Navigation Links
QIAGEN Expands Liquid Biopsy Pipeline with AR-V7 Test in Prostate Cancer
Date:3/31/2017

HILDEN, Germany and GERMANTOWN, Maryland, March 31, 2017 /PRNewswire/ --

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it is commercializing the Research use only AdnaTest Prostate Cancer Panel AR-V7 to detect the androgen receptor splice variant 7 (AR-V7) from liquid biopsies to investigate resistance to potential drugs for advanced prostate cancer. QIAGEN has acquired an exclusive worldwide license from Johns Hopkins University for detecting the AR-V7 biomarker in all sample and cell types through nucleic acid tests such as polymerase chain reaction (PCR) or next-generation sequencing (NGS). Johns Hopkins researchers have used AdnaTest technology in studies to evaluate the expression of AR-V7 messenger RNA in prostate cancer patients.

"Our AdnaTest workflow unlocks an important biomarker for clinical research to provide for the development of prostate cancer diagnostics in the future. Providing accurate insights from circulating tumor cells in a blood sample, our AR-V7 solution is a significant addition to our portfolio of non-invasive liquid biopsies for Personalized Healthcare," said Thierry Bernard, Senior Vice President and Head of QIAGEN's Molecular Diagnostics Business Area. "We are pleased to partner with the pioneering researchers at Johns Hopkins in developing this workflow. We plan to make the AdnaTest kit commercially available this year, as a Sample to Insight solution for clinical researchers."

Click here for the full press release

https://www.qiagen.com/about-us/press-releases/pressreleaseview?ID={55C014E9-91D1-4E5E-8FF0-822B2224081A}&lang=en

Contacts: 

QIAGEN 

Investor Relations            
John Gilardi    
+49-2103-29-11711        
e-mail: ir@QIAGEN.com             
           
Public Relations
Dr. Thomas Theuringer
+49-2103-29-11826  
e-mail: pr@QIAGEN.com


'/>"/>
SOURCE QIAGEN N.V.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. QIAGEN Joins CANCER-ID Consortium for Liquid Biopsy Workflows
2. New Study Published in Lancet Respiratory Medicine Highlights QIAGENs QuantiFERON-TB Potential to Predict Active Tuberculosis Risk in Infants
3. QIAGENs QuantiFERON-TB Test Wins Tender for Testing of Republic of Korea Armed Forces Recruits
4. How These Research Services Stocks are Faring? -- Myriad Genetics, Qiagen, INC Research, and La Quinta
5. QIAGEN Enhances Bioinformatics Portfolio with Acquisition of OmicSoft
6. QIAGEN Announces Comprehensive Range of Enhancements for GeneReader NGS System
7. Research and Markets - Global Cervical Cancer Diagnostic Testing Market Growth of 6%, 2016-2020 with Becton, Hologic & Qiagen Dominating
8. Research Reports Coverage on Services Stocks -- Myriad Genetics, Qiagen, INC Research, and La Quinta
9. QIAGEN GeneReader NGS System to Relaunch in U.S. Market
10. QIAGENs GeneReader NGS System Streamlines Data Management for Labs
11. QIAGEN führt Flüssigbiopsie-Workflow für das GeneReader NGS-System ein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... Oct. 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Software and Consulting, LLC , and named its founder ... based in Tennessee , will operate ... expands EnvoyHealth,s service offerings for health care partners to ... "In an interoperable world, technology ...
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, the ... by Walgreens and pharmacy benefit manager Prime Therapeutics LLC ... brand, which included the unveiling of new signage at ... as well as at a few other company-owned facilities ... brand to patients, some of whom will begin to ...
(Date:10/2/2017)... 2017 The Rebound mobile app is poised to ... the tide of prescription drug addiction. The app empowers users ... and stepping down their dosage in a safe, controlled manner ... 2017; the first 100,000 people to sign up will enjoy ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health ... technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing ... form that can be easily incorporated into liquid products, while reducing costs to end ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
(Date:10/13/2017)... ... , ... “America On The Brink”: the Christian history of the United States ... creation of published author, William Nowers. Captain Nowers and his wife, Millie, have ... thirty years in the Navy. Following his career as a naval aviator and ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
Breaking Medicine News(10 mins):